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Little is known about the epidemiology of methicillin-
resistant Staphylococcus aureus (MRSA) in most Paciﬁ  c 
Island nations. Relatively high rates of MRSA have been 
reported in Polynesian people living outside the Paciﬁ  c 
Islands. To determine the prevalence and characteristics 
of MRSA, we assessed wound swabs from 399 persons 
with skin and soft tissue infection living in Samoa. MRSA 
was isolated from 9% of study participants; 34 of the 196 
S. aureus isolates were MRSA. Five MRSA genotypes 
were identiﬁ   ed; the 3 most common were USA300, the 
Queensland clone, and a sequence type 1 MRSA strain that 
shares <85% homology with the sequence type 1 MRSA 
strain common in the region (WA MRSA-1). The Southwest 
Paciﬁ  c MRSA clone was identiﬁ  ed but accounted for only 
12% of MRSA isolates. The high prevalence of MRSA 
in Samoa provides impetus for initiatives to improve 
antimicrobial drug resistance surveillance, infection control, 
and antimicrobial drug use in Paciﬁ  c Island nations.
I
nfections caused by methicillin-resistant Staphylococcus 
aureus (MRSA) have become a global health concern 
during the past 2–3 decades. The epidemiology of MRSA 
has demonstrated marked geographic variation in the 
prevalence and genotypes of MRSA (1,2), and recent reports 
from many parts of the world indicate that the prevalence 
and diversity of MRSA continue to increase (3,4). Studies 
of the global epidemiology frequently have not included 
MRSA obtained from persons living in developing nations. 
The prevalence and genetic variation of MRSA infection 
in most Paciﬁ  c Island nations remain unknown. The only 
study of MRSA in the Paciﬁ  c was conducted after a report 
in 2004 of an increased incidence of MRSA infection in 
Polynesian people in Hawaii (5). This study showed that 
most MRSA infections in Hawaii were caused by the 
USA300 MRSA strain (6).
Relatively high rates of MRSA infection have been 
reported in Polynesian people living outside the Paciﬁ  c 
Islands region, including in Alaska, Australia, and New 
Zealand, and have been attributed to infection with the 
Southwest Paciﬁ  c clone of MRSA (sequence type [ST] 
30 SCCmec type IV, also referred to as Western Samoan 
phage pattern [WSPP] MRSA or the Oceania strain) (7–
10). The Southwest Paciﬁ  c clone of community-associated 
MRSA was identiﬁ  ed in New Zealand in 1992 (11). The 
ﬁ  rst isolate and many subsequent isolates of this strain were 
from persons in New Zealand who had some association 
with Samoa. The Southwest Paciﬁ  c MRSA clone has now 
spread as far as Europe and South America (4,12). This 
MRSA strain has been postulated to have arisen from 
a pandemic penicillin-resistant S. aureus strain, known 
as phage type 80/81, that caused serious hospital- and 
community-acquired infections during the 1950s (13).
Samoa is an independent nation in the Southwest 
Paciﬁ  c, with a population of ≈180,000 persons (Samoan 
Statistics Department, www.spc.int/prism/wstest/index.
htm; Figure). Samoa has a small and developing economy 
predominantly comprising remittances from Samoan 
persons living overseas, agriculture, and tourism. The gross 
domestic product per capita was US $2,987.90 in 2008 
(http://data.un.org). Life expectancy in Samoa is 74.9 years 
for women and 68.5 years for men, and the infant mortality 
rate is ≈22.3 per 1,000 live-born infants. The publicly 
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referral hospital in Apia; in addition, Samoa has 7 district 
hospitals (14). Several outreach and integrated community 
health services provide primary health care services, such 
as clinics and vaccinations.
Samoa gained independence from New Zealand in 
1962; a large Samoan population resides in New Zealand. 
In New Zealand, infections caused by S. aureus, whether 
methicillin susceptible or resistant, are more common 
in Maori and Polynesian persons than in other ethnic 
groups (15–17). Antimicrobial drug resistance is routinely 
monitored in New Zealand through testing of bacterial 
isolates from specimens taken for diagnostic purposes. In 
2008, 9% of S. aureus isolates were methicillin resistant, 
but this rate varied considerably among different parts of 
the country, with rates as high as 13%–16% in hospitals in 
the Auckland area (18).
In Samoa, as in many other developing countries, 
antimicrobial drug resistance is not systematically 
monitored. The microbiology service at the main public 
hospital in Apia performs antimicrobial drug susceptibility 
testing only when speciﬁ  cally requested by the treating 
doctor. This testing is infrequent, and the results are not 
regularly collated (V. Kini, pers. comm.). Testing for 
antimicrobial drug susceptibility requires equipment, 
resources, and a high level of expertise and quality 
assurance—requirements that are beyond the means of 
many laboratories in the developing world. If a high rate 
of antimicrobial drug resistance exists in Samoa, it would 
substantially affect this relatively poor country with 
relatively high rates of infectious diseases. We performed a 
systematic study to assess the prevalence and characteristics 
of MRSA isolated from wound swabs from persons with 
skin and soft tissue infection living in Samoa.
Methods
During the summer of 2007–2008, a study investigator 
(J.A.S.) collected S. aureus isolates from persons with 
skin and soft tissue infection. Review of patient notes was 
used to identify hospital patients who had skin lesions. All 
ambulatory patients who attended a clinic during the visit 
by J.A.S. and any family members who accompanied them 
were asked if they had a skin lesion. All persons with a skin 
lesion were invited to participate in the study; <5 persons 
declined to participate. At hospitals, participants included 
inpatients and outpatients, but this information was not 
recorded. No attempt was made to categorize infections 
as hospital acquired or community acquired, although the 
source of the wound was recorded.
All participants had skin and soft tissue infection, but 
this infection was not always the primary reason for contact 
with health services. Skin and soft tissue infection was 
deﬁ  ned as increasing pain, warmth, induration, erythema, 
or purulent discharge. Swabs were collected twice from 
patients who had separate lesions on the upper and lower 
body. If a patient had >1 infected site in the same region 
(e.g., upper body), only the larger lesion was swabbed.
Patient data collected included demographic 
information (age, sex, occupation, and village of residence) 
and recent exposure to health services (use of antimicrobial 
drugs in the last month and contact with health services in 
last 3 months). We attempted to include persons of different 
ages, both sexes, and various occupations.
The Lower South Ethics Committee in New Zealand, 
and the Health Research Council in Samoa gave ethical 
approval for the study. Participants were given an 
information sheet about the research and a small card 
explaining, in Samoan, how to take care of wounds. The 
study investigator explained the purpose of the study in 
Samoan, and the consent form was printed in Samoan and 
in English.
Swabs were taken after the wound was cleaned with 
sterile water. Swabs were placed into Amies transport 
media (Fort Richard Laboratories, Auckland, New 
Zealand), stored on ice, and transported to the laboratory at 
1 of the 2 main hospitals. All swabs were processed within 
12 hours after collection. Swabs were spread onto sheep 
blood agar containing aztreonam (6 mg/L) and incubated 
for 16–24 hours. A catalase test was performed on colonies 
suspected to be S. aureus, and catalase-positive colonies 
were identiﬁ  ed by using a latex agglutination test (BBL 
Staphyloslide Latex Test, Becton Dickinson, Sparks, MD, 
USA). S. aureus isolates were transported on a nutrient 
agar slope to LabPLUS (Auckland, New Zealand).
In New Zealand, antimicrobial drug susceptibility 
testing was performed by using disk diffusion for penicillin, 
and agar dilution breakpoint testing for cotrimoxazole, 
doxycycline, erythromycin, gentamicin, oxacillin, and 
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Figure. Map of Samoa, showing the 2 main islands, Upolu and 
Savai’i, and the capital Apia. Reproduced with permission from 
Oxford Cartographers (www.oxfordcartographers.com). MRSA, Samoa
vancomycin in accordance with Clinical and Laboratory 
Standards Institute methods and interpretive standards 
(19–21). MRSA isolates were tested by disk diffusion for 
susceptibility to ciproﬂ  oxacin and clindamycin, including 
inducible clindamycin resistance. Additional fusidic acid 
and mupirocin disk diffusion susceptibility testing was 
performed when required to assist with identiﬁ  cation of 
MRSA strains.
MRSA isolates were tested for the genes encoding 
for Panton-Valentine leukocidin (PVL) by PCR (22). 
Multilocus sequence typing (23); spa typing (24); and if 
necessary, pulsed-ﬁ   eld gel electrophoresis (PFGE) of 
SmaI-digested genomic DNA were used to identify and 
characterize MRSA strains. StaphType software version 
1.5 (Ridom GmbH, Würzburg, Germany) was used to 
assign spa types. We compared spa types by using the 
BURP (based upon repeat pattern) algorithm and excluding 
spa types with <5 repeats and setting a maximum cost of 
4 between members of a spa group cluster. PFGE banding 
patterns were analyzed with BioNumerics software version 
5.1 (Applied Maths, Saint-Martens-Latern, Belgium) 
by using the Dice coefﬁ  cient and unweighted pair group 
method with arithmetic averages, at settings of 0.5% 
optimization and 1.5% position tolerance.
Categorical data are expressed as proportions and 95% 
conﬁ  dence intervals (CIs), calculated by the modiﬁ  ed Wald 
method. Statistical signiﬁ  cance of comparative categorical 
data was examined by using the χ2 test.
Results
A total of 423 swabs were obtained from skin and soft 
tissue infections of 399 persons at 8 locations on the 2 main 
islands of Samoa (Upolu and Savai’i) and a smaller island, 
Manono. The 8 locations were the main public hospital in 
Apia (the capital on Upolu), the main public hospital on 
Savai’i, 5 district hospitals around the main islands, and 
community-based clinics on Manono.
Infections in skin and soft tissue were in wounds from 
falls, cuts, dog bites, car accidents, and burns; as well as 
boils and carbuncles. Many were described as po’u, a 
Samoan term for idiopathic tropical ulcer. Twenty-four 
persons each had swabs from 2 separate lesions. Even 
though we did not categorize infections as hospital acquired 
or community acquired, we were able to infer likely place 
of acquisition from the description of the wound: 20 (5%) 
of 399 represented infections of surgical sites, which were 
hospital acquired; 335 (84%) represented community-
acquired infections, such as impetigo; po’u; boils; or 
infections of wounds resulting from dog bites, machete 
cuts, or assaults. We were not able to further classify the 
remaining 44 (11%) infections.
S. aureus was isolated from 196 (46%, 95% CI 42%–
51%) of the 423 wound swabs and from 187 (47%, 95% 
CI 42%–52%) of the 399 study participants. S. aureus was 
more likely to be obtained from children <5 years of age 
than from persons in other age groups (37 [70%] of 53 
compared with 150 [43%] of 346; p<0.001) and less likely 
in persons currently or recently treated with antimicrobial 
drugs (84 [38%] of 224, compared with 103 [59%] of 175 
persons who were not; p<0.001) (Table 1).
Thirty-four (17%, 95% CI 13%–23%) of the 196 S. 
aureus isolates were methicillin resistant. MRSA was 
isolated from 8% (95% CI 6%–11%) of the 423 wound 
swabs and from 9% (95% CI 6%–12%) of the 399 study 
participants. Almost 1 in 5 of the 187 participants with S. 
aureus had MRSA (34/187, 18%, 95% CI 13%–24%). The 
basic demographic features of persons with MRSA did not 
differ substantially from those with methicillin-susceptible 
S. aureus (MSSA). Recent antimicrobial drug use and 
recent health care were not associated with an increase in 
MRSA infections. For example, the proportion of persons 
with recent health care exposure from whom MRSA was 
isolated (23/262, 9%) did not differ signiﬁ  cantly from the 
proportion of persons without recent health care exposure 
(11/137, 8%).
Participants lived in 165 villages around Samoa. 
We detected S. aureus in participants from 102 villages. 
In terms of place of domicile, MRSA was widespread 
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No. (%, 95% CI) 
S. aureus positive  MSSA MRSA
No. participants  399 187 (47, 42–52)  153 (38, 34–43)  34 (9, 6–12) 
Male sex  263 121 (46, 40–52) 95 (36, 31–42)  26 (10, 7–14) 
Age, y† 
  <5  53 37 (70, 56–81)‡ 33 (62, 49–74)  4 (8, 3–18) 
  5–15  93 50 (54, 44–64) 44 (47, 38–57)  6 (7, 3–14) 
  16–59  195 79 (34–48)  60 (31, 25–38)  19 (10, 6–15) 
 > 60 58 21 (36, 25–49)  16 (28, 18–40)  5 (9, 3–19) 
Antimicrobial drug treatment in previous month 224 84 (38, 31–44)§  67 (30, 24–36)  17 (8, 5–12) 
Health care contact in previous 3 months 262 108 (41, 35–47)  85 (32, 27–38)  23 (9, 6–13) 
*MSSA, methicillin-susceptible Staphylococcus aureus, MRSA, methicillin-resistant S. aureus; CI, confidence interval. 
†Median age, y (range) of study participants: All, 32 (0–89); S. aureus positive, 24 (0–84); MSSA positive, 26 (0–84); MRSA positive, 36 (0–76). 
‡p<0.001, S. aureus positive vs. study population >5 y of age. 
§p<0.001, S. aureus positive vs. no antimicrobial drug treatment in the previous month. RESEARCH
throughout Samoa and was isolated from persons from 
27 villages. There did not appear to be any geographic 
clustering associated with residence close to the main 
public hospital in Apia, although MRSA was more likely 
to be isolated from residents of Upolu, the main island 
on which Apia is located, than from residents of Savai’i, 
the less-populated and less-developed island. MRSA was 
isolated from 11% of participants from Upolu, but from 
only 3% of participants from Savai’i.
Of the 153 MSSA isolates from 187 participants, 124 
(81%) isolates were resistant to penicillin, but resistance 
to any other antimicrobial drug was uncommon. Of the 
34 MRSA isolates, 22 were resistant only to β-lactams. 
Of the remaining 12 MRSA, 8 were ciproﬂ  oxacin  and 
erythromycin resistant, 2 were erythromycin resistant with 
inducible clindamycin resistance, and 2 were ciproﬂ  oxacin 
resistant. All MRSA isolates were susceptible to 
cotrimoxazole, doxycycline, gentamicin, and vancomycin, 
and none had constitutive clindamycin resistance.
Except for the MRSA isolates identiﬁ  ed as type ST1 by 
multilocus sequence typing, all other MRSA belonged to a 
known MRSA strain (Table 2). Seven of the 9 ST1 isolates 
had indistinguishable PFGE proﬁ   les. The ST1 MRSA 
isolates had 82% homology by PFGE typing with another 
ST1 MRSA strain common in the region (the Australian 
WA MRSA-1).
Antimicrobial drug resistance proﬁ  le was associated 
with strain (Table 2). All isolates of the USA300 strain were 
ciproﬂ  oxacin resistant, and most also were erythromycin 
resistant. All of the Queensland clone and Southwest 
Paciﬁ  c clone MRSA, and 8 of the 9 ST1 MRSA isolates, 
were resistant only to β-lactams.
Discussion
Considerable concern exists internationally about 
increasing levels of antimicrobial drug resistance (25). 
Consequences include treatment failure, the need to use 
newer antimicrobial drugs to achieve treatment goals, the 
adverse effects frequently associated with these newer 
drugs, increased expenditure, and longer hospital stays. In 
developing countries, such as Samoa, an additional concern 
exists: when resistance to less expensive antimicrobial 
drugs becomes widespread, the more expensive 
antimicrobial drugs are simply not available (26). As in 
many other developing countries (27), use of antimicrobial 
drugs is extremely high in Samoa. More than 60% of all 
prescriptions dispensed in hospitals and private pharmacies 
include an antimicrobial drug (28). No current data are 
available on the prevalence of antimicrobial drug resistance 
in Samoa. In other countries, high levels of antimicrobial 
drug use correlate with high levels of resistance (29). 
In addition, inadequate dosing and poor adherence by 
patients may also increase the development of resistance 
(25). Anecdotal evidence indicates these practices also are 
common in Samoa.
In Samoa, children <5 years of age were more likely 
than persons in other age groups to have skin and soft tissue 
infection caused by S. aureus; however, the prevalence 
of MRSA infections were similar in children, adults, and 
elderly persons. Participants who had reported recent 
antimicrobial drug use were less likely to have S. aureus, 
but their prevalence of MRSA did not differ signiﬁ  cantly 
from those who did not report recent antimicrobial drug 
use. The lack of association between MRSA prevalence 
and health care exposure or antimicrobial drug use was 
surprising; however, the data on antimicrobial drug use 
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Table 2. Strains identified among the MRSA isolates, Samoa, summer 2007–2008* 
No. (%) 
isolates Strain† MLST type 
No. (%) PVL-positive 
isolates spa type (% of strain) 
Antimicrobial drug susceptibility 
(% of strain) 
10 (29)  USA300  ST8  9 (90)  t008 (100)  Resistant to ciprofloxacin and 
erythromycin (80); resistant to 
ciprofloxacin (20) 
9 (26)  Queensland clone  ST93  9 (100)  t3949 (56), t202 (44)‡  Resistant only to ȕ-lactams (100) 
9§ (26)  – ST1  0 t1853 (78), t6080 (11)¶  Resistant only to ȕ-lactams (89); 
resistant to erythromycin (11) 
4 (12)  Southwest Pacific/ 
WSPP/Oceania clone 
ST30  4 (100)  t019 (100)  Resistant only to ȕ-lactams (100) 
2 (6)  AK3 ST5  0 t002 (50), t1265 (50)#  Resistant to erythromycin** (50); 
resistant only to ȕ-lactams (50) 
*MRSA, methicillin-resistant S. aureus; MLST, multilocus sequence typing; PVL, Panton-Valentine leukocidin; WSPP, Western Samoa Phage Pattern. 
†International MRSA strain designations, except for AK3, which is a New Zealand designation for a community-associated MRSA strain common in New 
Zealand.
‡spa type t3949 (11–17–23–17–17–17–16–16–25) is a single-repeat variant of t202 (11–17–23–17–17–16–16–25). The extra repeat is shown in 
boldface.
§Only 8/9 ST1 MRSA isolates were available for PVL PCR, spa typing, and pulsed-field gel electrophoresis (PFGE) typing. Seven of the 8 isolates had 
indistinguishable PFGE profiles, and the eighth shared 87% homology. 
¶spa type t6080 (07–23–21–17–13–13–34–16–13–33–13) is a single-repeat variant of t1853 (07–23–21–17–13–34–16–13–33–13). The extra repeat is 
shown in boldface.
#spa type t1265 (26–23–17–34–17–20–17–12–12–12–16) is a variant of t002 (26–23–17–34–17–20–17–12–17–16). The differing repeats are shown in 
boldface.
**This isolate also had inducible clindamycin resistance.  MRSA, Samoa
may not be entirely reliable. A previous study found that 
many Samoans are unclear about which medicines were 
antimicrobial drugs (30). Most of the health care exposure 
reported in our study related to primary care exposure, and 
most of the MRSA strains isolated are typically associated 
with community acquisition (31). Even though most 
participants had community-onset skin and soft tissue 
infection, more detailed information about diagnosis and 
place of acquisition would have been valuable.
Few data are available on the prevalence of MRSA 
in the community in nonindustrialized countries. The 
World Health Organization has identiﬁ   ed a need to 
strengthen monitoring of antimicrobial drug prescriptions 
and resistance and has funded pilot programs to achieve 
this (25,32). In this study in Samoa, MRSA was isolated 
from 9% of all participants, and 18% of participants from 
whom S. aureus was isolated had MRSA. Although we 
attempted to include a wide range of persons in the study, 
we cannot be sure that some groups in our sample were 
not overrepresented or underrepresented. Carrying out 
such research is difﬁ  cult in a country such as Samoa, where 
research and laboratory infrastructure are not ideal. Ability 
to speak Samoan, knowledge of Samoan culture, and 
previous experience of living in Samoa were essential for 
the success of the project.
We found that the diversity of MRSA isolates in 
Samoa that caused skin and soft tissue infection was 
similar to that in Denmark, a country of >5 million 
persons (3). We expected that isolates of the Southwest 
Paciﬁ  c clone MRSA would be the predominant MRSA 
strain, but these were in the minority. The high prevalence 
of USA300 and Queensland clone MRSA might reﬂ  ect 
the amount of travel between Samoa and the United States 
and Australia, respectively. The Queensland clone is now 
common in the Australian states of New South Wales and 
the Northern Territory in addition to Queensland (33). 
However, the large number of isolates of the Samoa ST1 
MRSA clone and the isolation of almost equal numbers of 
3 different MRSA clones suggest that the situation may 
not be that simple.
The Samoa ST1 MRSA isolates were distinct by both 
PFGE and spa typing from the community-associated 
ST1 MRSA strain commonly found in Australia and New 
Zealand, WA MRSA-1 (33). The Samoa ST1 MRSA 
isolates shared only 82% homology by PFGE with WA 
MRSA-1. WA MRSA-1 isolates are typically spa type 
t127, which does not cluster by BURP analysis with the 
spa types (t1853 and t6080) of the Samoa ST1 MRSA. 
In addition, the WA MRSA-1 strain is characterized 
by fusidic acid resistance and often also mupirocin or 
erythromycin resistance, whereas the Samoa ST1 MRSA 
isolates generally were resistant only to β-lactams. The 
Samoa ST1 MRSA isolates also were distinct from the 
USA400 ST1 MRSA strain with which they shared only 
80% homology by PFGE. The Samoa ST1 MRSA strain 
might have originated in the Paciﬁ  c. However, MRSA with 
spa type t1853 have also been isolated in New Zealand, 
mainly from patients in the Auckland area, since at least 
2008 (34).
Three of the 5 strains that we identiﬁ  ed among MRSA 
isolates in Samoa (the USA300, Queensland, and Southwest 
Paciﬁ  c strains) typically are associated with community 
acquisition (31). The Samoa ST1 MRSA strain is also 
likely to be predominantly associated with community-
acquired infections. ST1 is recognized as a prominent 
genetic background of community-associated MRSA (35). 
The Samoa ST1 MRSA shares >80% homology by PFGE 
typing with 2 other ST1 community-associated MRSA 
strains: WA MRSA-1 and USA400. WA MRSA-1 caused 
the ﬁ  rst cases of community-associated MRSA infection in 
previously healthy persons in Western Australia in the early 
1990s, and USA400 was the strain isolated from the ﬁ  rst 
cases of community-acquired MRSA in the United States 
(31). The Samoa ST1 MRSA strains are not multiresistant, 
another feature typical of community-associated MRSA 
strains. On the other hand, none of the isolates of this strain 
carried the PVL genes, which are commonly found in 
community-associated MRSA. However, WA MRSA-1 is 
also PVL negative. Clearly, further characterization of the 
Samoa ST1 MRSA is warranted.
Evidence suggests that community-associated MRSA 
strains, particularly USA300, are more easily transmitted 
and might be more virulent than other S. aureus strains 
(31). In North America, approximately one third of persons 
with community-acquired USA300 MRSA infection 
require hospital admission (36). Moreover, community-
associated MRSA is no longer just a problem in the 
community; it also has become a common cause of health 
care–associated infections (37). Hospital-acquired USA300 
infections are more likely than community-acquired 
USA300 infections to be invasive and be associated with 
treatment failures (36). Thus, increases in the prevalence, 
severity, and complexity of diseases caused by globally 
successful community-associated MRSA strains are likely 
to be associated with increased illness, death, and cost. 
Economic analyses have consistently demonstrated that 
MRSA infections are associated with higher cost than are 
MSSA infections; although these studies have focused 
primarily on the costs associated with hospital care (38). 
None of these studies have investigated the consequences 
of MRSA in the developing world, yet the effects of disease 
are considerable (39).
Although reducing MRSA infection in the Samoan 
community is desirable, no controlled trials have 
demonstrated effective means of reducing community-
associated MRSA infections in a community setting. 
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Recommendations to reduce transmission of community-
associated MRSA include washing hands, caring for and 
covering wounds, not sharing contaminated personal 
items, appropriately disposing of contaminated waste, and 
appropriately prescribing antimicrobial drugs (40). Any 
interventions have substantial resource implications for a 
developing nation but must start with reliable surveillance 
of antimicrobial drug susceptibility, which is essential to 
monitor, control, and manage antimicrobial drug resistance. 
Thus, there is a clear need to assist developing countries 
with performing quality antimicrobial drug susceptibility 
testing and surveillance.
The results of our study, together with future 
surveillance efforts, can be used to provide information 
for local prescribing; the prevalence of MRSA in Samoa 
is high, and empiric prescription of antimicrobial drugs 
needs to account for this high prevalence. For example, 
we advocate that any patient in Samoa suspected to have 
serious, invasive S. aureus infection have adequate cultures 
and antimicrobial drug susceptibility testing performed. 
S. aureus infection in such a patient should be treated 
with vancomycin and a β-lactamase–stable penicillin 
drug until laboratory results are available. Patients with 
uncomplicated skin and soft tissue infections requiring 
antimicrobial drug treatment should receive cotrimoxazole 
or, if the patient cannot tolerate sulfonamides, clindamycin. 
Boils or furuncles should be treated by drainage, infection 
control, and wound care, with antimicrobial drugs reserved 
for complications.
We identiﬁ  ed a wide range of genotypes of MRSA 
that were causing wound infections in a small Paciﬁ  c 
Island nation. Our hope is that this study will provide a 
starting point for future research into antimicrobial drug 
resistance in the Paciﬁ  c and provide impetus for initiatives 
to improve antimicrobial drug use in Paciﬁ  c Island nations. 
Antimicrobial drug resistance is a global concern that does 
not respect national boundaries; consequently, countries 
need to assist each other in addressing the problem.
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